Finding – Page 18

AstraZeneca’s Fasenra Gains FDA Approval for Eosinophilic Granulomatosis with Polyangiitis, Expanding Treatment Options for Rare Autoimmune Disease

12 months ago talkbio0Tagged Approved, asthma medication, AstraZeneca, Autoimmune Diseases, biology (field), eosinophilic, Eosinophilic granulomatosis with polyangiitis, Granulomatosis, GSK 's, Infrequent, Nucala, Systemic Vasculitis, United States Food and Drug Administration

AstraZeneca, Fasenra, FDA approval, eosinophilic granulomatosis with polyangiitis (EGPA), rare autoimmune disease, biologic treatment, asthma medication, GSK’s Nucala

Triple Threat: 50% of Women Delay or Skip Medical Care Due to Affordability, Access, and Negative Experiences

12 months ago talkbio0Tagged Access, Affordability, barriers, Delayed medical care, disparities, Experience, Gender, Health care facility, Healthcare equity, issues, Negative, Women 's healthcare

Women’s healthcare, Delayed medical care, Affordability issues, Access barriers, Negative healthcare experiences, Gender disparities in healthcare, Healthcare equity

Terns Pharmaceuticals’ Oral GLP-1 Drug Demonstrates Promising Weight Loss Results

1 year ago talkbio0Tagged Glucagon-Like Peptide 1, Laridae, Obesity, Oral cavity, TERN-601, Weight Loss

Terns Pharmaceuticals, Oral GLP-1, Weight Loss, Obesity Treatment, TERN-601

Ivonescimab Outperforms Keytruda in Phase 3 Lung Cancer Trial, Reducing Disease Progression Risk by 49%

1 year ago talkbio0Tagged Akeso, Ivonescimab, Keytruda, Non-Small Cell Lung Carcinoma, PD-L1, pembrolizumab, Phase 3 trial, Positive, summit

Ivonescimab, Keytruda, Non-Small Cell Lung Cancer (NSCLC), Phase 3 Trial, HARMONi-2, PD-L1 Positive, Pembrolizumab, Summit Therapeutics, Akeso.

Terns Pharmaceuticals’ Oral GLP-1R Agonist TERN-601 Shows Promising Weight Loss in Phase 1 Trial

1 year ago talkbio0Tagged Agonist, Laridae, Obesity, Oral cavity, phase 1 trial, TERN-601, Weight Loss

Terns Pharmaceuticals, TERN-601, Oral GLP-1R Agonist, Phase 1 Trial, Weight Loss, Obesity Treatment

GSK’s Depemokimab Shows Promising Results in Phase 3 Trials, Reducing Asthma Attacks by Half

1 year ago talkbio0Tagged Asthma, Depemokimab, IL-5 Inhibitor, Inflammation, Long-Acting Biologic, Phase 3 trials, Severe (severity modifier), SmithKline Beecham

GSK, Depemokimab, Asthma, Phase 3 Trials, Long-Acting Biologic, IL-5 Inhibitor, Severe Asthma, Type 2 Inflammation

FDA Limits Use of Invivyd’s COVID-19 Prophylactic as New Variants Dominate

1 year ago talkbio0Tagged authorization, COVID19 (disease), Emergency Situation, Immunocompromised Host, Invivyd, Pemgarda, United States Food and Drug Administration, Variant

Invivyd, COVID-19, Pemgarda, Emergency Use Authorization, FDA, Immunocompromised, Variants

Federal Agency Rejects J&J’s 340B Rebate Model, Vows to Take Action

1 year ago talkbio0Tagged Contact Role - Federal Agency, Gegenhalten, Health care facility, Johnson & Johnson, Policy, Programs - Publication Format, Rebate Model

340B Program, Johnson & Johnson, Rebate Model, Federal Agency Opposition, Healthcare Policy

Lilly’s Tirzepatide Demonstrates Significant Reduction in Diabetes Risk and Sustained Weight Loss in Overweight Adults

1 year ago talkbio0Tagged Adult, Diabetes, Eli, Eli Lilly, Mounjaro, Obesity, Overweight, Prediabetes syndrome, Risk Reduction, Sustained, Weight Loss, Zepbound

tirzepatide, diabetes risk reduction, sustained weight loss, overweight adults, pre-diabetes, obesity, Eli Lilly, Mounjaro, Zepbound

AstraZeneca Secures Landmark EU Approval for Imfinzi-Lynparza Combo in Endometrial Cancer Treatment

1 year ago talkbio0Tagged Approved, AstraZeneca, Combined Modality Therapy, EU, Imfinzi, Immunotherapy, Inhibitor, Lynparza, Malignant neoplasm of endometrium, Mismatch Repair, Mismatch Repair Deficiency, PARP1 gene, proficient

AstraZeneca, Imfinzi, Lynparza, endometrial cancer, EU approval, combination therapy, immunotherapy, PARP inhibitor, mismatch repair proficient, mismatch repair deficient